Phase i dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

Investigational New Drugs

Volumn 33, Issue 6, 2015, Pages 1206-1216

  Faivre, Sandrine J ^a   Olszanski, Anthony J ^b   Weigang Köhler, Karin ^c   Riess, Hanno ^d   Cohen, Roger B ^e   Wang, Xuejing ^f   Myrand, Scott P ^f   Wickremsinhe, Enaksha R ^f   Horn, Candice L ^f   Ouyang, Haojun ^f   Callies, Sophie ^f   Benhadji, Karim A ^g   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

^b FOX CHASE CANCER CENTER   (United States)

^c PARACELSUS MEDICAL UNIVERSITY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g Medical Oncology   (France)

Author keywords

Oral gemcitabine prodrug; Pharmacogenomics; Pharmacokinetics; Phase I study; Solid tumors

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CYTOKERATIN 18; DNA; LY 2334737; UNCLASSIFIED DRUG; DEOXYCYTIDINE; DEOXYURIDINE; GEMCITABINE; LY2334737; PRODRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; EDEMA; FEMALE; GENETIC POLYMORPHISM; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LIVER FAILURE; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DEOXYURIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PRODRUGS;

EID: 84947493293     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0286-7     Document Type: Article

References (25)

1. Gemzar Summary of Product Characteristics (SPC) http://agence-prd.ansm.sante.fr/html/par-eu/20110907-fr390-gemcitabinemylan-spc.pdf. Accessed 24 November 2014
2. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
3. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489
4. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
5. Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, Yasuda C, Kudo M (2006) Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 41:70-76
6. Takahashi Y, Mai M, Sawabu N, Nishioka K (2005) A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas 30:206-210
7. Pratt SE, Durland-Busbice S, Shepard RL, Donoho GP, Starling JJ, Wickremsinhe ER, Perkins EJ, Dantzig AH (2013) Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts. Mol Cancer Ther 12:481-490
8. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14:3477-3486
9. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW (1992) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20:849-855
10. Moysan E, Bastiat G, Benoit JP (2013) Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications. Mol Pharm 10:430-444
11. Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, Vaid RK, Zhang D, McCarthy JR (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52:6958-6961
12. Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH (2013) Human carboxylesterase 2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res 19:1159-1168
13. Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH (2011) Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 17:6071-6082
14. Yamamoto N, Nokihara H, Yamada Y, Uenaka K, Sekiguchi R, Makiuchi T, Slapak CA, Benhadji KA, Tamura T (2013) Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 71:1645-1655
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
16. Wickremsinhe ER, Lutzke BS, Jones BR, Schultz GA, Freeman AB, Pratt SE, Bones AM, Ackermann BL (2010) Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement. Anal Chem 82:6576-6583
17. Ueno T, Toi M, Linder S (2005) Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 59(Suppl 2):S359-S362
18. De Petris L, Brandén E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, Lewensohn R, Linder S, Lehtiö J (2011) Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer 47:131-137
19. Linder S, Olofsson MH, Herrmann R, Ulukaya E (2010) Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn 10:353-359
20. Sasieni PD (1997) From genotypes to genes: doubling the sample size. Biometrics 53:1253-1261
21. ENCODE Project Consortium (2011) A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 9:e1001046. doi: 10.1371/journal.pbio.1001046
22. Salazar R, Morales S, Gil-Martín M, Aguirre E, Oaknin A, Garcia M, Callies S, Wickremsinhe ER, Benhadji KA, Llombart A (2014) Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 73:1205-1215
23. Infante JR, Benhadji KA, Dy G, Fetterly G, Wee Ma W, Callies S, Adjei AA (2015) Phase 1 study of oral gemcitabine prodrug LY2334737 in combination with capecitabine in patients with advanced solid tumors. Investig New Drugs 33:432-439
24. Iyer SN, Ankala A, Singhal RS, Hegde MR (2013) Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population. Gene 524:35-39
25. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32-42